FDA Calls July PCAC Meeting on Seven Category 2 Peptides

Originally published April 2026. Corrected and updated August 15, 2026.

On April 16, 2026, the U.S. Food and Drug Administration published a Federal Register notice convening a meeting of the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to consider seven peptide bulk drug substances for possible inclusion on the section 503A Bulks List. The notice also established a public docket, FDA-2025-N-6895, for comment.^[1]

---

What the notice asked

The 503A Bulks List is a statutory list. A substance on it may be used by a licensed pharmacist or physician to compound a drug for an identified individual patient, under section 503A of the Federal Food, Drug, and Cosmetic Act.^[10] Substances get onto it through rulemaking, and FDA evaluates each nomination against four criteria set by final rule at 84 FR 4696: physicochemical characterization, safety, evidence of effectiveness, and historical use in compounding — then balances them.^[7]

The seven substances on the July agenda were BPC-157, KPV, TB-500, MOTS-c, Emideltide (delta sleep-inducing peptide), Epitalon, and Semax. Each was put to the committee twice — once as a free base, once as an acetate salt — for fourteen votes in all.^[3]

Each substance also came with a specific evaluated use, and those uses are narrower than the marketing around these peptides suggests:^[2]

An evaluated use is the use the committee was asked to weigh. It is not an FDA finding that the peptide works for that condition.

---

What happened at the meeting

The committee recommended six of the seven for the list. Emideltide was the only rejection.

Two honest caveats about that table. First, FDA published no official tallies, no summary minutes, and no transcript — as of August 15, 2026 the posted materials stop at the agenda, roster, briefing documents, voting questions, and slide decks.^[2] The numbers above are as reported by legal and trade press covering the meeting. Second, the vote totals differ by substance because they should: the final roster shows several standing and temporary members were seated only for specific substances, so the eligible-voter count ranged from 12 to 15.^[4]

Some outlets reported the Epitalon vote as 7-5-1. Only twelve members were eligible to vote on Epitalon, which is consistent with 7-4-1, so that is the figure we use.

---

FDA's own reviewers recommended against all seven

This is the part most coverage compressed into a clause, and it is the most important fact for anyone weighing what the vote means.

FDA's multidisciplinary review team — drawing on the Office of Compounding Quality and Compliance, the Office of New Drugs, and the Office of Pharmaceutical Quality — proposed that none of the seven substances be added to the list. On BPC-157 the slides say it plainly: "A balancing of the criteria weighs against BPC-157 (free base) or BPC-157 acetate being placed on the 503A Bulks List," and "FDA is proposing that BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List."^[5] The same conclusion-and-recommendation structure runs through the day-two deck.^[6]

The committee then voted the other way on six of seven. Advisory committees can and do disagree with FDA staff, but it is uncommon, and it makes FDA's eventual response less predictable than a routine "yes" vote would.

The scientific objections FDA raised were concrete:

• Characterization. FDA's conclusion slide for BPC-157 states that "BPC-157 acetate is not well-characterized."^[5]
• Impurities. FDA identified two classes: peptide-related impurities (from incomplete coupling, truncations, side reactions) and synthesis-process-related impurities (isomers, free amino acids, residual solvents, coupling reagents). It noted having "no information regarding the nature of individual impurities" and "no information on impurity limits/testing results."^[5]
• Immunogenicity. FDA flagged the potential for an immune response when these peptides are formulated for injection or as a nasal spray, driven by aggregation and by those impurities.^[5]
• Conflated bulks. The meeting opened with a dedicated FDA talk titled "FDA Bulk Drug Substance Discussion of Conflated Bulks and Common Name Challenges" — about trade names that map to different amino acid sequences and molecular weights depending on the supplier, so a prescription does not identify what the patient actually receives.^[5] TB-500 is the textbook case: the name is used for both a seven-amino-acid fragment and the full 43-amino-acid thymosin beta-4 protein.

FDA also reminded the committee what listing does not do. A substance on the 503A list is still not FDA-approved, is not required to carry labeling with directions for use, is not made under current good manufacturing practice, and is not subject to mandatory adverse-event reporting.^[5]

---

Who voted, and why composition is worth knowing

The final roster is a public FDA document, and it is worth reading if you want to interpret narrow margins.^[4] Alongside academic pharmacists, physicians, and a USP representative, several voting members are affiliated with longevity, wellness, and direct-to-consumer clinical practices. Temporary members were seated substance by substance for subject-matter expertise.

We report that as a fact about the roster, not as an accusation. Advisory committees routinely include practitioners with relevant commercial experience, and disclosure and waiver rules exist for exactly that reason. But when six votes come in at margins of one to three, who was in the room is part of reading the result honestly.

Coverage of the vote in the general press leaned political, framing it as a defeat for FDA career staff. That framing is not something we can verify from primary documents, and we are not adopting it. What the primary documents do support is narrower and more useful: FDA's reviewers said no to all seven, and the committee said yes to six.

---

What has to happen next — and what has not happened

A PCAC recommendation is not self-executing. For any of these peptides to actually become compoundable under 503A, FDA has to:

1. Publish a proposed rule adding the substance to the 503A Bulks List;
2. Run a notice-and-comment period;
3. Publish a final rule.

As of August 15, 2026, none of that has started. A Federal Register sweep of FDA documents published since the meeting returns nothing on the 503A Bulks List or these peptides. FDA's own bulk-substance pages carry "content current as of" stamps that all predate the meeting, meaning no list has changed.^[8] FDA also issued no press release and no compounding risk alert on peptides in the weeks after the vote.

Law-firm commentary generally expects rulemaking to run from late 2026 into 2027 or later. Treat any specific timeline as an estimate, not an FDA statement.

---

What this means for you

If you are already working with a prescriber and a compounding pharmacy: nothing changed on July 24. A licensed pharmacy that begins compounding these substances from bulk today is not operating on a new legal footing. The right question for your prescriber is what their pharmacy's plan is if and when FDA issues a proposed rule — not what they are doing now.

If you are considering moving off gray-market sourcing: the enforcement picture around unapproved peptides has not loosened. FDA's import alerts and internet-seller enforcement programs remained active through the summer, and separately, drug manufacturers have begun suing research-use-only peptide sellers directly.

If you are new to peptides: read FDA Peptide Categories Explained and What Are Compounding Pharmacies? first. The single most common misreading of this story is treating an advisory vote as approval. The evidence base for most of these peptides remains thin regardless of what any list says.

What to watch:

1. FDA summary minutes and the meeting transcript, which had not been posted as of August 15, 2026.
2. A proposed rule in the Federal Register — the first real signal FDA intends to act.
3. A second peptide PCAC meeting, which law firms report FDA signalled for five more substances including GHK-Cu. No FDA notice, docket, or date exists for it yet.

---

References

1. [1]

   U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Federal Register. 2026. LinkFederal Register notice

   FR Doc. 2026-07361, published April 16, 2026. Establishes the July 23-24, 2026 PCAC meeting and public docket FDA-2025-N-6895. As of August 15, 2026 this remains the most recent Federal Register action on the 503A Bulks List and these peptides.

2. [2]

   U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” FDA.gov. 2026. LinkRegulatory document

   The official meeting page, including each substance's FDA-evaluated use and the full list of posted event materials. FDA had not updated it with an outcome as of August 15, 2026.

3. [3]

   U.S. Food and Drug Administration. “PCAC Meeting July 23-24, 2026: Questions.” FDA.gov. 2026. LinkRegulatory document

   The official voting-questions document. Fourteen separate votes: free base and acetate salt were put to the committee separately for each of the seven substances. FDA did not publish the tallies.

4. [4]

   U.S. Food and Drug Administration. “July 23-24, 2026 PCAC Meeting — Final Meeting Roster.” FDA.gov. 2026. LinkRegulatory document

   Lists standing and temporary voting members and which substances each was seated for. This is why the number of votes cast differs by substance.

5. [5]

   U.S. Food and Drug Administration. “July 23, 2026 PCAC Meeting — FDA Presentations.” FDA.gov. 2026. LinkRegulatory document

   FDA's own day-one slide deck, including the opening talk on conflated bulks and common-name challenges and the review team's recommendation against inclusion.

6. [6]

   U.S. Food and Drug Administration. “July 24, 2026 PCAC Meeting — FDA Presentations.” FDA.gov. 2026. LinkRegulatory document

   FDA's day-two slide deck, covering Emideltide, Epitalon, and Semax.

7. [7]

   U.S. Food and Drug Administration. “PCAC July 23-24, 2026 — Briefing Document Introduction.” FDA.gov. 2026. LinkRegulatory document

   Sets out the four statutory evaluation criteria and the balancing test codified at 84 FR 4696 (February 19, 2019), and names the nominators for each substance.

8. [8]

   U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” FDA.gov. 2026. LinkRegulatory document

   FDA's page defining the 503A Bulks List and the interim-policy categories. Checked August 15, 2026; FDA's own 'content current as of' stamp was May 14, 2026, meaning no list changed in the window.

9. [9]

   U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee.” FDA.gov. 2026. LinkRegulatory document

   The standing federal advisory committee that reviews nominated bulk drug substances and advises FDA on inclusion in the 503A and 503B lists.

10. [10]

    U.S. Food and Drug Administration. “Compounding Laws and Policies: Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.” FDA.gov. 2026. LinkRegulatory guidance

---

---

Related content

Guide

The July 2026 PCAC Peptide Vote

Our full hub: tallies, evaluated uses, evidence grades, and what the vote does and does not change.

Tool

Peptide Legal Status Tracker

Source-checked status for every peptide we track, updated August 15, 2026.

News

FDA Peptide Categories Explained

How the interim-policy categories differ from the statutory 503A Bulks List.

Peptide

BPC-157

Recommended 8-6-1 as reported. Still not compoundable.

Peptide

TB-500

The peptide FDA's 'conflated bulks' talk describes best.

---